Article Versions Notes

Suki M, Imam A, Amer J, Milgrom Y, Massarwa M, Hazou W, Tiram Y, Perzon O, Sharif Y, Sackran J, et al. SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals. 2025; 18(8):1118. https://doi.org/10.3390/ph18081118

Suki, Mohamad, Ashraf Imam, Johnny Amer, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Yariv Tiram, Ofer Perzon, Yousra Sharif, Joseph Sackran, and et al. 2025. "SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic" Pharmaceuticals 18, no. 8: 1118. https://doi.org/10.3390/ph18081118

Suki, M., Imam, A., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., Alon, R., Lourie, N., Hershko Klement, A., Shibli, S., Safadi, T., Raz, I., Khalaileh, A., & Safadi, R. (2025). SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals, 18(8), 1118. https://doi.org/10.3390/ph18081118